Date: 2012-08-29
Type of information: Production agreement
Compound: ARG201
Company: Angel Biotechnology (UK) Argentis Pharmaceuticals (USA)
Therapeutic area: Autoimmune diseases
Type agreement: manufacturing
production
Action mechanism: ARG201 uses precise, low dose of highly purified native type 1 bovine collagen prepared by a proprietary purification method to induce oral immune tolerance in SSc patients\' immune system to type 1 collagen. Low dose OT is mediated by induction of antigen specific regulatory T lymphocytes that secrete immunoregulatory cytokines such as IL-4, IL-10 and transforming growth factor (TGF)-?.
Disease: systemic sclerosis
Details: The biopharmaceutical contract manufacturer Angel Biotechnology has signed a framework agreement with arGentis Pharmaceuticals which establishes the parameters of future contracts for the development and manufacture of their collagen product, ARG201, a treatment for the life-threatening autoimmune disease, systemic sclerosis.
Financial terms:
Latest news:
